Cercle’s core product is the Cercle Biomedical Graph™, an AI-driven platform that ingests and transforms raw, de-identified women’s healthcare data into high-quality, real-time insights. The Graph acts as a mediator between patient records and LLMs, anonymizes data, and is HIPAA- and GDPR-compliant. Since its November 2023 introduction the platform has been used by US Fertility, Boston IVF, and Eurofins Genoma and has captured and analyzed more than one billion anonymized data points. Cercle will use the seed funding to expand beyond the fertility market, broaden its global footprint, and advance its LLM capabilities and product engineering. The company aims to serve providers, payers, and pharma across reproductive health, menopause, women’s oncology, and rare diseases that disproportionately affect women. The company notes the Graph has not been evaluated by the FDA and is not classified as a medical device.

Total raised

$6M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2024